MFMahsa Fattahi

Mahsa Fattahi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mahsa Fattahi has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Itraconazole-Induced Apoptosis in Candida glabrata ( Nakaseomyces glabratus ) Biofilms: Role of ROS and CgPDR 1 Mutations (K274N, D1082G, and S343F) in Resistant Clinical Isolates

    byĀ Farnaz Valizadeh, Mahsa Fattahi, Ensieh Lotfali, Nasrin Motamed

    Background: Nakaseomyces glabratus exhibits intrinsic tolerance to azole antifungals, frequently mediated by gain-of-function (GOF) mutations in the transcription factor CgPDR1 . While efflux-mediated resistance is well established, its potential interaction with oxidative stress–dependent cell death pathways in biofilms remains insufficiently characterized. Materials and Methods: Fifteen clinical isolates (susceptible, n = 5; resistant, n = 10) were analyzed under planktonic and biofilm conditions. Antifungal susceptibility to itraconazole (0.03–32 µg/mL) was determined, while apoptosis and intracellular reactive oxygen species (ROS) were quantified using Annexin V/PI staining and fluorescence-based assays, respectively. The role of oxidative stress was evaluated using ascorbic acid co-treatment. CgPDR1 mutations were identified by sequencing. Results: Resistant isolates exhibited significantly elevated minimum inhibitory concentration (MIC) values (up to 32 µg/mL) and a high prevalence of CgPDR1 mutations (K274N: 100%; D1082G: 30%; S343F: 10%). Itraconazole induced a marked increase in ROS production and apoptosis in susceptible biofilms (Annexin V + ā‰ˆ 70%), whereas resistant isolates demonstrated attenuated ROS generation and reduced apoptosis (ā‰ˆ10%, p < 0.01). Although ascorbic acid significantly decreased ROS levels in susceptible isolates, it did not alter MIC values or restore antifungal susceptibility. Conclusions: CgPDR1 GOF mutations are associated with a coordinated resistance phenotype in N. glabratus biofilms, characterized by enhanced drug tolerance and reduced ROS-mediated apoptosis. These findings support a multifactorial resistance model and identify K274N as a potential population-specific biomarker.

  • Open Access

    Molecular Identification and Evaluation of Resistance to Antifungal Drugs in Candida Species Isolated From Diaper Rash of Neonates

    byĀ Fariba Shirvani, Mahsa Fattahi, Abdollah Karimi, Shahnaz Armin, Seyed Alireza Fahimzad, Sedigheh Rafiei Tabatabaei, Roxana Mansour Ghanaei, Fatemeh Fallah, Alireza Firooz, Shahrzad Tabatabaee, et al.

    Background: Diaper dermatitis, also recognized as diaper rash, is one of the most frequent skin conditions in neonates. Materials and Methods: A total of 100 babies participated in the study. Eligibility included neonates aged 5–28 days and full‐time diaper wearers. Participants were categorized into two groups: those who received systemic antibiotics for at least 1 week and those who did not, in order to assess the impact of antibiotic use on diaper rash. The antifungal susceptibility was determined based on the reference method M60 CLSI. Results: Among 100 specimens, 50 cases suffered from Candida infection. The Candida albicans (34, 68%) was reported as the most frequent species, followed by C. kefyer (10, 20%), C. tropicalis (4, 8%), and C. glabrata (2; 4%). Nystatin, posaconazole, voriconazole, amphotericin B, ketoconazole, and clotrimazole showed high activity against all species (Minimum Inhibitory Concentration ≤ 0.125 µg/mL). The resistance frequency of C. albicans to itraconazole and fluconazole was 65.5% and 12.7%, respectively (minimum inhibitory concentration ≄ 16 and minimum inhibitory concentration ≄ 64, respectively). The allele with the K143R and Y132F replacements displayed the strongest characterized combination effect, with 14‐fold and 18‐fold increased itraconazole and fluconazole MICs, respectively. Conclusion: The selection of itraconazole and fluconazole‐resistant isolates of candida among pediatric population may be a concern because C. albicans can be involved in invasive infections. The treatment of recurrent invasive candidiasis, needing repeated course of fluconazole or itraconazole, could be a risk factor for selecting resistant isolates. In addition, as the liposomal amphotericin B is no more commercialized in our country, a higher drug selection pressure for azoles may be expected in the future.


  • Open Access

    A State of the Art Review on the Recalcitrant Candidiasis as a Clue of Inborn Errors of Immunity in Newborns

    byĀ Mahsa Fattahi, Pegah Tamimi, Aliasghar Ghaderi, Mohammad Reza Fazlollahi, Zahra Pourpak

    Background: Defects in the development or function of the immune system are characteristic of inborn errors of immunity (IEI), a diverse group of inherited disorders. IEI can manifest in various ways during the neonatal stage, posing a challenge in their identification and treatment. The family who have a background of IEI, including a previous instance of an infant’s death caused by infection, sepsis from bacteria in children requiring intravenous (IV) antibiotics, and failure to thrive, as well as newborns with fungus infection such as chronic recalcitrant candidiasis. This review sought to clarify the significance of recalcitrant candidiasis in identifying IEI in newborns. To enhance healthcare strategies, we make it a priority to keep data on managing difficult candidiasis up‐to‐date and consider the potential benefits of implementing these newborn screening programs for IEI. Methods: In this review, we highlight the state‐of‐the‐art recalcitrant candidiasis‐based diagnostic strategies of the IEI in newborns. The article is organized as follows: In Section 2, different clinical features of immunodeficiencies in newborns will be summarized, with emphasis different pathogens are associated in different types of immunodeficiencies. Also, different types of candidiasis which are related to each type of IEI will be presented in Section 3. The challenges diagnostic tests to identify of IEI (screening and definite diagnosis) and the type of diagnostic tests for confirmation of recalcitrant candidiasis from bench to bedside will be covered in Sections 4–6. The concept of a patient’s treatment who has recalcitrant candidiasis will be addressed along with this paper in Section 7. Implication for practice will be discussed in Section 8. Results: The most previous study shows antifungal treatment failure, caused by resistant or tolerant activity toward commonly used antifungal medications, is a probable cause for the presence of recalcitrant candidiasis in newborns. It is important for clinicians to consider the possibility of underlying conditions and order specific tests to identify the type of Candida and determine the best treatment for newborns with persistent candidiasis. Conclusions: To sum up, remember to consider immunodeficiency when deciphering abnormal treatment response for candidiasis. Resistant or dose‐dependent candidiasis lab results in a neonate may signal a potential immunodeficiency, leading to more medical and lab examinations to confirm or rule it out. It can be said that the recalcitrant candidiasis may be considered as a clue about the nature of the underlying immune deficiency. A comprehensive knowledge of recalcitrant candidiasis is imperative in identifying IEI, underscoring the crucial role of well‐trained local pediatricians in early detection. The importance of implementing an early detection program for IEI couldn’t be overstated, as it has been proven to significantly enhance quality of life and life expectancy by allowing for timely medical interventions in cases of IEI and significantly reduces medical expenses.

  • Open Access

    Preparation and Optimization of Voriconazole Gel 0.25% for Topical Delivery in Terbinafine Resistance Dermatophytosis: In Vitro and Pilot Animal Study

    byĀ Saman Ahmad Nasrollahi, Mahsa Fattahi, Ensieh Lotfali, Atefeh Naeimifar, Fatemeh Amiri, Aliasghar Ghaderi, Pegah Tamimi, Shayan Zamani, Ali Khamesipoor, Alireza Firooz

    Background: There have been several reports of patients with chronic recalcitrant diseases, rare presentations, recurrent relapses, and treatment failure. This study aimed to formulate and evaluate the safety profile of topical voriconazole (VCZ) gel 0.25% for effective drug delivery to the skin as an adjuvant therapy in cases of extensive dermatophytosis. Methods and Materials: VCZ 0.25% topical gel was manufactured by Carbomer, and its characteristics such as pH, viscosity, density, and microbial growth were examined at 40 ± 2°C/75 ± 5% RH for six months. The animals were divided into three groups (2:2:2) randomly. The hair from the back of guinea pigs (test sites: 2 cm 2 ) was shaven, and their skin was scraped slightly using a single‐use scalpel. Afterward, terbinafine drug–resistant Arthroderma benhamiae suspension (50 μL) was inoculated to a 2 cm 2 surface area of the shaven skin. Results: Agar culture of scrapings from the area indicated the infection development. The fabricated VCZ topical gel exhibited acceptable stability. The VCZ 0.25% gel was proved to be an effective treatment in a time‐dependent base, in comparison with terbinafine (1%) as a positive control ( p < 0.05). Furthermore, using gel base VCZ 0.25% reduced the period of full treatment of A. benhamiae infection to five days, compared with the 12‐day complete cure by terbinafine. Conclusion: Results from the present study indicated that gel‐based VCZ could be utilized as topical therapy for dermatophytosis. Due to the increase of drug‐resistant dermatophyte spp., indications of gel base VCZ 0.25% for treating dermatophytosis are believed to increase accordingly.

  • Treatment strategies for controlling antifungal resistance in Candida onychomycosis

    byĀ Pegah Tamimi, Aliasghar Ghaderi, Alireza Firooz, Shirin Sayyahfar, Mahsa Fattahi

    • 3 August 2025
      • Vol.Ā 11
    Open Access

    Caspofungin therapy in prosthetic valve endocarditis and candidemia due to itraconazole-resistant Candida glabrata (Nakaseomyces glabratus): A case report

    byĀ Mohamad Rafi Khurgami, Mahsa Fattahi, Effat Hosseinali Beigi, Pegah Tamimi, Aliasghar Ghaderi, Golnaz Hajiesmail

    Candidemia is a prevalent nosocomial bloodstream infection with a high mortality rate. Involvement of heart valves by Candida spp. after candidemia can result in native and prosthetic valve endocarditis as biofilm-related infections. This report aimed to introduce a case of a 13-year-old male with bloodstream infection and prosthetic valve endocarditis, caused by itraconazole-resistant Candida glabrata (Nakaseomyces glabratus). Despite undergoing itraconazole for 4 weeks, the patient did not improve. White colonies were identified as C. glabrata (N. glabratus) by Restriction Fragment Length Polymorphism-Polymerase Chain Reaction. The isolate was resistant to itraconazole (MIC=8 µg/mL) but susceptible to amphotericin B and caspofungin. Based on concerns about biofilm-related resistance, treatment was switched to caspofungin for 5 weeks. He continued to do well and showed no signs of relapse during his 6-month follow-up. This study explored the importance of antifungal susceptibility testing in handling complicated infections, as well as the potential of caspofungin in the treatment of cases of fungal bloodstream infections and endocarditis.

  • Reactive oxygen species-inducing itraconazole and its anti-biofilm activity against resistant Candida parapsilosis sensu lato biofilm cells isolated from patients with recalcitrant onychomycosis

    byĀ Monireh Kamali, Aliasghar Ghaderi, Pegah Tamimi, Alireza Firooz, Mansour Nasiri Kashani, Azin Ayatollahi, Farnaz Valizadeh, Maryam Fattahi

    Candida parapsilosis was introduced as the second most responsible for nail involvement. The colonization of biotic and abiotic surfaces by Candida spp. can result in the formation of biofilms, which possess a high level of resistance to typical antifungal agents. Since Candida spp. can produce biofilm mass on the surface of the nails, dermatologists should consider appropriate antifungals to eliminate both the planktonic and biofilm cells. The aim of this research was to determine the antifungal efficacy of itraconazole against C. parapsilosis sensu lato biofilm formations, in addition to its static effects. Ten C. parapsilosis sensu lato isolates were enrolled in this study. The use of itraconazole results in the accumulation of reactive oxygen species (ROS) during treatment. In order to verify the correlation between ROS and itraconazole-induced cell death, the viability of cells was analyzed by administering the ROS scavenger Ascorbic acid. The apoptotic features of itraconazole were analyzed using the Annexin V-FITC method. Based on current data, it was found that the generation of intracellular stresses by itraconazole is not observed in cells upon ROS inhibition, emphasizing the importance of intracellular ROS in the apoptotic mechanism of itraconazole. Targeting the oxidative defense system is a powerful point to use ROS-inducing antifungals as a superior choice for more effective therapies in case of recalcitrant onychomycosis. Graphical Abstract


  • Open Access

    Fabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea

    byĀ Samin Fallah Pakdaman, Aniseh Samadi, Mahsa Fattahi, Atefeh Naeimifar, Fatemeh Amiri Ardehali, Yasaman Ketabi, Saman Ahmad Nasrollahi, Alireza Firooz

    Background & Aim: Rosacea is a chronic inflammatory, multifactorial disease for which combination therapy could be an effective treatment. In this study, we evaluate the effect of the combination therapy of brimonidine 0.33% and ivermectin 1% as a single cream for the treatment of papulopustular rosacea. Method: A stable and appropriate formulation was prepared by adding the aqueous phase to the lipid phase while being stirred. The stability and physicochemical properties of the formulation were evaluated under accelerated conditions. Twelve patients (36–60 years) with mild to moderate papulopustular rosacea and a Demodex count of five or more were treated with the combination of brimonidine 0.33% and ivermectin 1% cream. Clinician's Erythema Assessment (CEA), Patients Self‐Assessment (PSA), skin erythema (Ī”E) and lightness (Ī”L), and skin biophysical parameters including transepidermal water loss (TEWL), skin hydration, pH, and sebum content, as well as erythema and melanin index and ultrasound parameters, were measured before treatment and 4 and 8 weeks after. Adverse drug reactions were also recorded. Results: CEA and PSA decreased significantly from 3 to 2 after 8 weeks, respectively ( p ‐value = 0.014 for CEA and 0.010 for PSA). Ī”E and Ī”L, as well as skin erythema index and TEWL improved after 8 weeks of treatment ( p < 0.05). Two patients withdrew from the study in the first week because of local adverse effects; one developed flushing following treatment and left the investigation after 4 weeks and another patient withdrew from the study after 4 weeks due to deciding to become pregnant. Conclusion: Eight‐week treatment with the combination of brimonidine 0.33% and ivermectin 1% was shown to be effective for improvement of erythema and inflammatory lesions in mild to moderate papulopustular rosacea.


  • Recalcitrant dermatophyte infections: identification and risk factors

    byĀ Pegah Tamimi, Mahsa Fattahi, Alireza Firooz, Aliasghar Ghaderi, Azin Ayatollahi, Mansour Nasiri Kashani, Ahmed Alkhen

    Introduction: Recalcitrant dermatophytosis is an emerging phenomenon that occurs worldwide, and Trichophyton indotineae is currently the prominent cause.Materials and methods: Skin specimens from patients with tinea infection were obtained by scrubbing and then sectioned into three fragments. Two fragments were subjected to direct microscopic examination and culture, while the third portion was utilized in the PCR method.Results: Isolates were morphologically identified as Trichophyton mentagrophytes/interdigitale complex (n = 60 [83.33%]), Microsporum canis (n = 8 [11.11%]), Trichophyton rubrum (n = 3 [4.16%]), and Epidermophyton floccosum (n = 1 [1.38%]). Among 60 T. mentagrophytes complex isolates, 53 (88.33%) were classified as T. indotineae and seven as T. interdigitale genotype II. The disease duration was longer in the T. indotineae group (P = 0.035). Both Gradient PCR and skin‐sampling methods yield similar results in terms of positive and negative cases (P = 1.0000). The time patients stopped their medication did not impact the positive case numbers (P = 0.803). Gender had no effects on the frequency (P = 0.699). Familial contamination, dermatologic disorder, and other underlying conditions did not differ in the two group infections (P > 0.05). Steroid usage is strongly associated with the emergence of tinea infection (P < 0.04). The duration of antifungal administration had a substantial effect on the emergence of resistant organisms (P = 0.05).Conclusions: Steroid usage, T. indotineae involvement, and prolonged exposure to antifungals were the solid and influential factors in recalcitrant involvement. Regarding quick and suitable diagnosis and treatment, which is essential in preventing recalcitrant cases, we suggest that direct skin sample PCR can meet the demands.


  • Open Access

    Efficacy and Safety of Phoenix dactylifera L. Leaf Extract (WartOverĀ®) in the Treatment of Cutaneous Warts: A Randomized, Double‐Blind, Placebo‐Controlled Trial

    byĀ Azin Ayatollahi, Alireza Firooz, Safoura Shakoei, Reza M. Robati, Nima Aramipour, Setayesh Sadeghi, Fateme Tavakoli-Far, Mohammad Reza Niavand, Mohammad Saber, Mahsa Fattahi, et al.

    Background. Cutaneous warts are caused by the human papillomavirus that can affect a patient’s quality of life. Current treatments have high cost, low efficacy, adverse effects, and recurrence. Therefore, novel therapeutic approaches are needed. Complementary and Alternative Medicines (CAMs) are gaining popularity as a therapeutic approach. Phoenix dactylifera L. (date palm) is used in folk medicine to treat warts. Antiviral effects of P. dactylifera L. have been demonstrated due to its polyphenolic compounds, especially gallic acid and tannins in various studies. So, this trial evaluates the efficacy and safety of P. dactylifera L. leaf extract (formulated as WartOverĀ®) as a novel treatment for cutaneous warts. Study Design. Based on the results of our previously published pilot clinical trial and the CONSORT guideline, this randomized, double‐blind, and placebo‐controlled study was performed on 70 eligible patients divided into intervention and placebo groups (N = 35/per group). Every 2 weeks, patients were examined to assess the rate of complete clearance, duration of treatment, patient satisfaction (measured using a Likert scale), and occurrence of any adverse effects and recurrence in a maximum of 12 weeks of treatment and at the 6‐month follow‐up. Results. Based on the intention‐to‐treat (ITT) analysis approach, complete clearance was achieved in 24 patients in the intervention group (68.57%; confidence interval 95% = 0.51–0.81), which was significantly higher than that in the placebo group (8.57%; CI 95% = 0.02–0.23, p < 0.0001). The time to complete clearance was 7.6 weeks (mean ± SD: 53.30 ± 17.17 days). The treatment was very satisfactory (Likert score of 4.24 ± 1.15 (mean ± SD)) with no recurrence or adverse effects. Conclusion. WartOverĀ® is a novel efficacious treatment for cutaneous warts with minimal risk for adverse events or recurrence. Due to the rising popularity of CAM approaches in medicine, including herbal medicines, WartOverĀ® can be a valuable choice for clinicians against cutaneous warts. This trial is registered with IRCT20200509047352N2.